SION Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

5 Analyst Rating

Wall Street analysts forecast SION stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SION is 40.00 USD with a low forecast of 24.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 43.840

Low

24.00

Averages

40.00

High

46.00

Current: 43.840

Low

24.00

Averages

40.00

High

46.00

BTIG

Kambiz Yazdi

Buy

initiated

$50

2025-11-18

Reason

BTIG

Kambiz Yazdi

Price Target

$50

2025-11-18

initiated

Buy

Reason

BTIG analyst Kambiz Yazdi initiated coverage of Sionna Therapeutics with a Buy rating and $50 price target. Sionna Therapeutics is a clinical-stage biotech company developing therapies for the treatment of cystic fibrosis, the analyst tells investors in a research note. BTIG thinks SION-719 will meet benchmarks for its high-impact Phase 2a readout in mid-2026.

Freedom Capital

Buy

initiated

$38

2025-10-17

Reason

Freedom Capital

Price Target

$38

2025-10-17

initiated

Buy

Reason

Freedom Capital initiated coverage of Sionna Therapeutics with a Buy rating and $38 price target. Completed Phase 1 studies have shown clean safety and target exposures and support two paths forward -- SION-719 as a Trikafta add-on and SION-451 in proprietary combinations with complementary modulators, the analyst tells investors in a research note. While the upcoming Phase 2a initiation and ongoing dual-combination readouts are expected to drive short-term momentum, the company's focus remains on long-term value creation, the firm says.

JonesResearch

initiated

$46

2025-09-08

Reason

JonesResearch

Price Target

$46

2025-09-08

initiated

Reason

JonesResearch initiated coverage of Sionna Therapeutics (SION) with a Buy rating and $46 price target. Sionna is clinical stage biotech advancing novel cystic fibrosis drugs, the analyst tells investors in a research note. The firm says the company has developed two NBD1 stabilizers, SION-451 and SION-719, which, when in combination with complementary modulators, are likely superior to the standard of care, Vertex's (VRTX) Trikafta.

RBC Capital

Brian Abrahams

Sector Perform

initiated

$22

2025-09-03

Reason

RBC Capital

Brian Abrahams

Price Target

$22

2025-09-03

initiated

Sector Perform

Reason

RBC Capital analyst Brian Abrahams initiated coverage of Sionna Therapeutics with a Sector Perform rating and $22 price target. The company's CFTR modulators could position it as a long-term key player in the cystic fibrosis space, the analyst tells investors in a research note. However, existing treatments create a high bar and there are questions as to how meaningfully de-risking Sionna's next set of clinical data in mid-2026 will be, the analyst tells investors in a research note. As such, RBC would wait for more progress before stepping into the shares.

Valuation Metrics

The current forward P/E ratio for Sionna Therapeutics Inc (SION.O) is -20.88, compared to its 5-year average forward P/E of -9.90. For a more detailed relative valuation and DCF analysis to assess Sionna Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.90

Current PE

-20.88

Overvalued PE

-4.20

Undervalued PE

-15.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.09

Current EV/EBITDA

-15.05

Overvalued EV/EBITDA

-3.24

Undervalued EV/EBITDA

-10.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SION News & Events

Events Timeline

No data

News

4.5

12-02NASDAQ.COM

Stocks Decline Amid Increasing Bond Yields

4.5

12-01NASDAQ.COM

Stocks Decline as Increasing Bond Yields Trigger Cautious Investor Sentiment

4.5

12-01Benzinga

Crude Oil Rises More Than 1%; November Sees Decline in ISM Manufacturing PMI

People Also Watch

Frequently Asked Questions

What is Sionna Therapeutics Inc (SION) stock price today?

The current price of SION is 43.84 USD — it has increased 2.5 % in the last trading day.

What is Sionna Therapeutics Inc (SION)'s business?

Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.

What is the price predicton of SION Stock?

What is Sionna Therapeutics Inc (SION)'s revenue for the last quarter?

Sionna Therapeutics Inc revenue for the last quarter amounts to -23.81M USD, decreased % YoY.

What is Sionna Therapeutics Inc (SION)'s earnings per share (EPS) for the last quarter?

Sionna Therapeutics Inc. EPS for the last quarter amounts to -15317000.00 USD, decreased % YoY.

What changes have occurred in the market's expectations for Sionna Therapeutics Inc (SION)'s fundamentals?

The market is revising No Change the revenue expectations for Sionna Therapeutics, Inc. (SION) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 96.50%.

How many employees does Sionna Therapeutics Inc (SION). have?

Sionna Therapeutics Inc (SION) has 41 emplpoyees as of December 15 2025.

What is Sionna Therapeutics Inc (SION) market cap?

Today SION has the market capitalization of 1.91B USD.